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Abstract
Background: Physical exercise reduces glucose levels and glucose variability in patients with type 2 diabetes. Acute
inspiratory muscle exercise has been shown to reduce these parameters in a small group of patients with type 2
diabetes, but these results have yet to be confirmed in a well-designed study. The aim of this study is to investigate
the effect of acute inspiratory muscle exercise on glucose levels, glucose variability, and cardiovascular autonomic
function in patients with type 2 diabetes.
Methods/design: This study will use a randomized clinical trial crossover design. A total of 14 subjects will be
recruited and randomly allocated to two groups to perform acute inspiratory muscle loading at 2 % of maximal
inspiratory pressure (PImax, placebo load) or 60 % of PImax (experimental load).
Discussion: Inspiratory muscle training could be a novel exercise modality to be used to decrease glucose levels
and glucose variability.
Trial registration: ClinicalTrials.gov NCT02292810.
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Background
Hyperglycemia is the main cause of the clinical mani-
festations and acute and chronic complications of
diabetes mellitus. Reducing glucose levels through
nonpharmacological [1, 2] and pharmacological ther-
apy is the cornerstone of type 2 diabetes management
[3, 4]. Goals for optimal diabetes management include
reducing glycated hemoglobin (HbA1c) levels to 7 %
and implementing a number of cardiovascular risk
reduction strategies [5, 6].
However, chronic complications of diabetes can de-
velop even when these targets are met. This can be
attributed to genetic and epigenetic factors [7], dis-
ruption of repair mechanisms [8], and, possibly, high
glucose variability even when optimal HbA1c levels
are achieved. Glucose variability is the fluctuation of
glucose levels during the day, including episodes of
hypoglycemia and hyperglycemia [9]. Measurement of
glucose levels in intersticium throughout the day by
continuous glucose monitoring systems [10, 11] or
periodic capillary blood-glucose measurements [12,
13] have been used to evaluate glucose variability.
Several conventional measures are available to quan-
tify this parameter and have been widely reported in
the literature over the past years [14, 15], including
the mean amplitude of glycemic excursions [16], the
standard deviation of glucose, and the mean of daily
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differences [17]. Non-conventional methods, which
use mathematical and statistical analysis of the dy-
namic characteristics of glucose levels, as measured
using continuous glucose monitoring systems,
through spectral analysis and symbolic analyses, were
recently reported [18].
Exercise training, consisting of aerobic exercise, resist-
ance exercise, or a combination of both, is a useful tool
for reducing HbA1c levels in type 2 diabetes [2, 19, 20].
It is also associated with several other benefits, including
improved blood pressure control [21], reduction of
skeletal muscle frailty [22], reduction of inflammation
[23], and improved cardiovascular autonomic function
[24]. Additionally, a recent study showed that an acute
bout of aerobic or resistance exercise is associated with
lower glucose variability [18], opening a new venue of
benefits to explore.
Considering that many diabetic patients, especially
those with autonomic neuropathy, have poor exercise
tolerance or are completely unable to perform con-
ventional exercises [25], alternatives should be sought.
Inspiratory muscle training is a modality that has
proven benefits in several clinical situations [26, 27],
such as improving cardiopulmonary capacity and nor-
malizing derangements in autonomic function [27, 28]. In
patients with type 2 diabetes, this exercise modality can
improve the strength and resistance of inspiratory muscles
[29] and reduce glucose levels and glucose variability [30].
We speculate that, in type 2 diabetes, beyond reflecting
the well-known improvement in insulin sensitivity in-
duced by muscle contractions, inspiratory exercise would
also yield improvements in cardiovascular autonomic
function [27, 28]. Thus, the aim of this study is to investi-
gate the effect of acute inspiratory muscle exercise on glu-
cose levels, glucose variability, and autonomic control in
patients with type 2 diabetes.
Methods/design
Study design
This study is a randomized clinical trial with a crossover
design.
Outcome measures
The difference in glucose levels before and after exercise
(evaluated by continuous glucose monitoring systems;
glucose level after exercise minus glucose level before
exercise) is the primary outcome measure. The sec-
ondary outcome measures are: (1) changes in glucose
variability, which will also be evaluated by continuous
glucose monitoring systems through conventional (mean
amplitude of glucose excursion, variation of glucose, co-
efficient of variation of glucose, and standard deviation
of glucose) and non-conventional indices (spectral ana-
lysis and symbolic patterns: no variation); (2) changes in
cardiovascular autonomic control, which will be evalu-
ated by blood pressure variability and heart rate variabil-
ity (measures of power spectral density of low frequency,
high frequency and very low frequency bands). Table 1
shows the measures that will be evaluated to achieve the
desired results.
Sample size and power calculation
According to preliminary results obtained in our labora-
tory [31], the sample size was estimated in 14 individuals
with type 2 diabetes, allowing for a dropout rate of 10 %.
This sample size would detect a 34 mg/dl difference in
glucose levels between the intervention inspiratory load
of 60 % and the placebo inspiratory load of 2 %, taking
into account a standard deviation of 30 mg/dl, a statis-
tical power of 80 %, and a type I error rate of 5 %.
WinPepi software was used to calculate the sample size.
Inclusion and exclusion criteria
The study will be conducted in patients with type 2
diabetes, diagnosed according to the National Diabetes
Data Group criteria [5]. The inclusion criteria will be
age 30 years and older, HbA1c between 7.5 and 10 %,
and stable clinical condition, to ensure safe performance
of the trial protocols. Patients will be recruited from the
Outpatient Endocrinology Clinic of Hospital de Clínicas
de Porto Alegre, Brazil. All study methods described are
in accordance with the CONSORT Statement [32].
The exclusion criteria will consist of: insulin treat-
ment, pregnancy, pulmonary disease (history of exercise-
induced asthma), cardiac arrhythmias, chronic kidney
disease (glomerular filtration rate <30 ml/min), exclusive
use of beta blockers as antihypertensive therapy, current
smoking, varicose veins, and musculoskeletal conditions
that would hinder safe completion of the proposed
exercise protocols.
Randomization
The randomization sequence will be generated by
computer. Randomization to the low-resistance inspira-
tory muscle exercise group (2 % of maximal inspiratory
pressure (PImax), placebo load) or the high-resistance
inspiratory muscle exercise group (60 % of PImax, ex-
perimental load) will be performed by an investigator
assigned exclusively to this task, who will not partici-
pate in the recruitment, assessment, or intervention
phases of the study.
Data collection
Patients will be instructed to attend on three different
days at the study laboratory for baseline evaluations,
as follows:
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 Day 1: Urine collection and fasting blood draw for
assessment of glucose, HbA1c, creatinine, and
microalbuminuria; physical examination; Ewing tests
for autonomic assessment; and completion of the
International Physical Activity Questionnaire.
 Day 2: Resting 12-lead electrocardiogram, inspiratory
muscle and pulmonary function tests.
 Day 3: Cardiopulmonary exercise testing.
Autonomic neuropathy evaluation
The presence of cardiovascular autonomic neuropathy
will be evaluated using digital electrocardiography
(VNS-Rhythm Neurosoft, Ivanovo, Russia) as previously
described [33] and the five noninvasive cardiovascular
tests proposed by Ewing [34], as standardized in our in-
stitution [35]. The heart rate, electrocardiographically
monitored, will be evaluated after 5 min of resting and
before and after deep breathing, the Valsalva maneuver,
and standing. Three tests will be used to evaluate the
heart rate response to (1) deep breathing, (2) lying-to-
standing heart rate ratio, and (3) a Valsalva maneuver.
Two tests of blood pressure control will be performed
during (1) orthostatic hypotension and (2) sustained
handgrip. Two or more abnormal test results will be
deemed diagnostic of cardiovascular autonomic neur-
opathy. Heart rate variation will be assessed while pa-
tients are asked to breathe deeply at a rate of six breaths
per minute while being monitored using three-lead
Table 1 Evaluated measures
Time point Data collection Measure Outcomes
Pre-evaluation Blood and urine analysis Glycemia, HbA1c, microalbuminuria
and creatinine
Metabolic responses




Survey Physical activity estimates
Inspiratory muscle test maximal inspiratory mouth
pressure (PImax)
Inspiratory muscle strength
Pulmonary function test maximum voluntary ventilation,
forced vital capacity, vital
capacity, forced expiratory
volume (1 s), forced expiratory
volume (1 s)/vital capacity and
forced expiratory volume
(1 s)/forced vital capacity
Pulmonary flow and volume
Rest electrocardiogram 12-lead electrocardiogram Electrical activity of the heart
Cardiopulmonary exercise testing VO2peak, VCO2peak, Rpeak, VEpeak,
VE⁄VO2peak, VE⁄VCO2peak
Ventilatory and metabolic variables
At rest Continuous glucose
monitoring system
Glucose concentration Glucose levels and variability
Biopac system Continuous recording
of blood pressure
Blood pressure and heart rate
variability in time and
frequency domains
Controlled ventilation Continuous glucose
monitoring system
Glucose concentration Glucose concentration
and variability
Biopac system Continuous recording
of blood pressure
Blood pressure and heart rate
variability in time and
frequency domains
Inspiratory muscle exercise





Glucose concentration Glucose levels and variability
Biopac system Continuous recording
of blood pressure
Blood pressure and heart rate




Glucose concentration Glucose concentration
and variability
Biopac system Continuous recording
of blood pressure
Blood pressure and heart rate
variability in time and
frequency domains
HbA1c, glycated hemoglobin; PImax, inspiratory mouth pressure; R, respiratory exchange rate; VCO2peak: carbon dioxide output; VE, minute ventilation; VO2peak,
peak oxygen uptake; VE⁄VO2: ventilatory equivalent for oxygen; VE⁄VCO2: ventilatory equivalent for carbon dioxide
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electrocardiography. The maximum and minimum heart
rate during each breathing cycle will be measured, and
the mean difference over six cycles will be calculated.
The heart rate ratio test will be performed after a period
of rest in the supine position, and heart rate variability
will be determined by calculating the maximal to min-
imal heart rate ratio: the ratio of the longest RR interval,
measured around the 30th beat after standing up, to the
shortest RR interval, measured around the 15th beat
after standing up. The Valsalva maneuver will consist of
forced exhalation into a mouthpiece with a pressure of
40 mmHg for 15 s, and the ratio of the maximum RR
interval after this maneuver to the minimum RR interval
during the maneuver will be calculated. Orthostatic
hypotension will be defined as a decrease of 30 mmHg
in systolic blood pressure when the individual voluntarily
changes from the supine to the standing position. Mea-
surements will be obtained at minutes 1 and 3 after
standing up. Sustained muscle contraction will be mea-
sured by a handgrip dynamometer. The dynamometer
will be first squeezed to maximum isometric contraction
in the dominant hand. The highest of three measure-
ments will be taken; then patients will be asked to hold
at 30 % maximum for 3 min. A rise in diastolic blood
pressure of < 10 mmHg is considered an abnormal
response.
Inspiratory muscle testing
Inspiratory muscle function testing will be performed
using a pressure transducer (MVD-500 V.1.1 Microhard
System; Globalmed, Porto Alegre, Brazil), connected to a
system containing two one-way valves (DHD Inspiratory
Muscle Trainer, Chicago, IL, USA) and equipped with a
2 mm diameter orifice to relieve facial muscle pressure.
Patients will be instructed to remain seated, with elbows
resting on the chair; a nasal clip will be used during all
maneuvers. The PImax will be determined after patients
take a deep breath at tidal volume, followed by slow
exhalation to residual volume, and then quickly perform
a maximal inspiration against the occluded circuit with a
small air leak. The test will be repeated at least three
times, with a 1 min interval between repetitions, to ob-
tain six measurements with <10 % variation [29, 36, 37].
The values obtained from the PImax readings will be
verified directly on the transducer. Predicted values will
be corrected for age and sex.
Pulmonary function
Measurements of forced vital capacity, vital capacity,
forced expiratory volume in 1 s, and their ratios (forced
expiratory volume (1 s)/vital capacity and forced expira-
tory volume (1 s)/forced vital capacity) will be obtained
using a computerized spirometer (Eric Jaeger GmbH,
Würzburg, Germany), as recommended by the American
Thoracic Society [38], and results will be expressed as a
percentage of predicted parameter. For maximum volun-
tary ventilation, subjects will be instructed to breathe as
deeply and quickly as possible for 15 s; volume measure-
ment will begin after the patient is able to achieve and
maintain maximum effort [38].
Cardiopulmonary exercise testing
Maximal functional capacity will be assessed by means
of an incremental exercise test to be performed on a
treadmill (Inbramed 10200, Porto Alegre, Brazil), using a
ramp protocol with a speed of 2–6 km/h and increasing
slope of 4–10 % to reach exhaustion in about 10 min [36].
A 12-lead electrocardiogram tracing will be obtained every
1 min (Nihon Khoden Corp., Tokyo, Japan), and blood
pressure will be measured every 2 min with a standard
cuff sphygmomanometer. During the test, gas exchange
variables will be measured breath-by-breath with a pre-
viously validated system (Metalyzer3B, CPX System;
Cortex, Leipzig, Germany). Ventilatory and metabolic
variables will be analyzed throughout the test. Peak
oxygen uptake (VO2peak) will be defined as the highest
value reached during the test.
Study intervention
After baseline evaluations, all patients will be instructed
to present to the laboratory, three times per week for
2 weeks, for completion of the intervention stage of the
study protocol, as follows:
 Day 1: Placement of the continuous glucose
monitoring system. Patients should arrive at
8:00 a.m. for device placement. Patients using beta
blockers will be advised to discontinue their
medication 24 hours before the next study visit.
 Day 2: Acute inspiratory muscle exercise protocol
(2 % or 60 % of PImax). Patients should arrive at
10:00 a.m. and will be instructed to rest in the
supine position for 10 min for collection of baseline
glucose, continuous blood pressure, and heart rate
measurements. Participants will then start controlled
ventilation for 10 min. A 40-minute interval will be
allowed to elapse before the start of acute inspiratory
muscle loading. Pursuant to random group alloca-
tion, participants will receive loading to 2 % of
PImax (low resistance, placebo load) for 10 min or
to 60 % of PImax (high resistance, experimental
load) until task failure. At the end of the exercise
protocol, a 10-min recovery record will be obtained.
Glucose levels will also be measured by capillary
sample before and after the protocol reported above.
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Arterial oxygen saturation (SpO2) mean arterial
pressure, end-tidal carbon dioxide, calf blood flow,
and calf vascular conductance will be measured
during all protocols.
 Day 3: Continuous glucose monitoring system
removal. Patients will be instructed to return to the
laboratory at noon for removal of the device.
One week following these interventions, all subjects
will return to the study facility to repeat these proce-
dures, but using another randomized load for inspiratory
muscle exercises.
The experimental sessions will take place at the
Hospital de Clínicas de Porto Alegre Exercise Patho-
physiology Research Laboratory. All experiments will
be performed in a temperature-controlled room and
all subjects will be instructed to refrain from consum-
ing caffeinated beverages and alcohol for at least
12 hours and from exercise for at least 24 hours prior
to the evaluation. Continuous assessment of blood-
glucose levels and blood pressure will be performed
before, during, and after all protocols. Patients will be
asked to follow their habitual diet and keep a detailed
food intake record across the 3 days of continuous
glucose monitoring system use.
Glucose variability evaluation
Subjects will be admitted to the laboratory at 8:00 a.m.,
24 hours before the acute inspiratory muscle exercise
session, for placement of the continuous glucose moni-
toring system sensor (Enlite Glucose Sensor, Medtronic
MiniMed Inc., Northridge, CA, USA). Glucose data are
obtained every 5 min, providing a total of 288 readings
per day.
Individuals will be instructed to perform at least four
capillary blood-glucose measurements per day, before
each meal, for calibration. The monitoring will be
performed by the patients themselves, with a digital
glucometer (Accu-Check Performa, Roche Diagnostics,
Mannheim, Germany). Along with the glucometer, diaries
will be delivered to patients, in which they should record
the glucose values at each measurement and also details
of all meals ingested during the period of continuous
glucose monitoring.
Glucose variability will be evaluated using conven-
tional and non-conventional analyses. Conventional ana-
lysis will be conducted using the statistical properties of
the glycemic series classically used [16, 39, 40] and non-
conventional analysis of glucose variability will be con-
ducted by application of two methods to the glucose
series, based on spectral analysis and symbolic dynamics.
Spectral analysis is a linear method that allows quantifi-
cation of the oscillatory components from a time series
by autoregressive models, and is widely applied to heart
rate and arterial pressure series [41]. Symbolic dynamics
relies on the calculation of Shannon entropy of the dis-
tribution of patterns lasting three measures and the clas-
sification of frequent deterministic patterns lasting three
measures, and distributes deterministic patterns of the
group into four variations [42].
Cardiovascular autonomic control evaluation
Cardiovascular autonomic control will be measured con-
tinually before the protocol (during a 10 min rest),
during the controlled ventilation plus acute inspiratory
muscle exercise protocol (2 % or 60 % of PImax), and
throughout the recovery period, using a noninvasive
blood pressure device (NIBP100D system; Biopac, Santa
Barbara, CA, USA) with a general purpose amplifier
module (DA100; Biopac), according to methodological
guidelines provided by Sherwood et al. [43]. This system
acquires the blood pressure wave at a sampling fre-
quency of 1000 Hz through a cuff placed on the middle
phalanx of the third finger. Beat-to-beat time series of
systolic blood pressure and pulse interval will be
constructed from blood pressure recording data; their
variances correspond to heart rate variability and blood
pressure variability, respectively. In addition, spectral
analysis, using an autoregressive model, will be applied
to estimate the center frequency and power of each
relevant oscillatory component [41]. The spectral bands
for human beings are defined as: very low frequency, 0.0
to 0.04 Hz; low frequency, 0.04 to 0.15 Hz; and high
frequency, 0.15 to 0.40 Hz, as described elsewhere [41].
Controlled ventilation
Individuals will be placed in the supine position for
measurement of respiratory rate, heart rate, SpO2 by
pulse oximetry, and mean arterial pressure, which will
be measured using an automated sphygmomanometer
(Dinamap 1846 SX/P, Critikon, Tampa, FL, USA) once
per minute during the test. The glucose and blood
pressure, calf blood flow (which will be measured by
venous occlusion plethysmography (Hokanson TL-400,
Bellevue, WA, USA)) will be recorded continuously.
Inspiratory volume will be assessed using a pneumo-
tachograph (Pneumotach3700 series, Hans Rudolph,
Kansas City, MO, USA). The end-tidal carbon dioxide
concentration will be measured by oxycapnography
(Takaoka Oxicap, São Paulo, Brazil) and maintained at
eupneic levels during both protocols via addition of CO2
to the inspiratory circuit. Participants will be instructed
to maintain a breathing frequency of 15 breaths per min
and a duty cycle (TI/TTot) of 0.7 by listening to an audio
signal with distinct inspiratory and expiratory tones, and
visual feedback will be displayed.
Schein et al. Trials  (2016) 17:38 Page 5 of 8
Acute inspiratory muscle exercise
This protocol was developed by Dempsey et al. [44] to
reduce diaphragm blood flow and cause fatigue. During
the protocol, individuals will breathe continuously
through a two-way valve (Hans Rudolph, 2600 series,
Shawnee, KS, USA) with low resistance (2 % of PImax)
connected to an inspiratory resistance obtained by a
threshold inspiratory muscle trainer (DHDInspiratory
Muscle Trainer, Chicago, IL) or, for higher inspiratory
pressures (60 % of PImax), to a POWERbreathe® inspira-
tory muscle trainer (Southam, UK). Inspiratory pressure
will be continuously recorded and displayed on a com-
puter screen shared through a television, providing
visual feedback; the 10-point Borg scale [45] will be used
to access inspiratory effort at task failure. Inability to
maintain breathing will be defined as a reduction of
PImax to less than 80 % of the prescribed value during
three consecutive breaths [38]. For the placebo experi-
ments conducted at 2 % of PImax, measurements will
cease at 10 min. The sequence of experiments, induction
of the inspiratory muscle metaboreflex (60 % of PImax),
or allocation to the placebo experiment (2 % of PImax),
will be randomized, and experiments will be conducted
1 week apart.
In both protocols, baseline data will be collected
during 10 min of spontaneous breathing. After this
period, a controlled ventilation protocol will be initi-
ated, and individuals instructed to maintain a breath-
ing frequency of 15 breaths per min and a duty cycle
(TI/TTot) of 0.7 by listening to an audio signal with
distinct inspiratory and expiratory tones for 10 min.
Calf blood flow will be measured by venous occlusion
plethysmography (Hokanson, TL-400, Bellevue, WA,
USA) every 10 s in the non-dominant lower limb.
Calf vascular conductance will be calculated as calf
blood flow divided by mean arterial pressure [46].
Blood pressure will be monitored once a minute
using an automated monitor (Dinamap, USA), and
heart rate will be monitored continuously throughout
the protocol.
Ethics and data protection issues
Participation will be voluntary, and all ethical princi-
ples of confidentiality and data protection will be
followed. All subjects will have to sign a standardized
informed consent form prior to participating in the
study. All procedures will be explained to partici-
pants, and information about the aim, design, poten-
tial risks and benefits, and all relevant details of the
study will be provided in the informed consent form.
The data obtained by the study will be available to
the participant and to any other authorized person,
and may be used anonymously for academic scientific
purposes. The study protocol was approved by the
Institutional Review Board of Hospital de Clínicas de
Porto Alegre, Brazil (number 14–0194) and registered
at ClinicalTrials.gov (NCT02292810).
Safety assessment
Data on all adverse events will be collected and included
in medical reports, which will be forwarded to the health
authorities. To ensure patient safety, if any adverse
events occur at any time during the study, participants
will be monitored for up to 4 weeks after study exit.
Statistical analysis
Data will be expressed as means and standard devia-
tions or medians and interquartile ranges for non-
parametric variables. Two-way analysis of variance
(ANOVA) for repeated measures will be used to evalu-
ate averages before and after acute inspiratory muscle
exercise, comparing the placebo (2 % of PImax) and
intervention (60 % of PImax) loads. Pearson cor-
relation coefficients will be used to evaluate the
association between components of cardiovascular
autonomic control and glucose levels. For nonpara-
metric variables, Spearman correlation will be used.
The statistical power will be 80 % and differences will
be considered significant for P < 0.05. All analyses will
be performed using SPSS Statistics for Windows,
version 20.0 (IBM Corp., Armonk, NY, USA).
Discussion
Exercise programs have traditionally emphasized aer-
obic exercise, because of its well-known cardiovascular
[47], metabolic [48], and autonomic benefits in type 2
diabetes [24, 49]. Resistance training also has favorable
effects on muscle strength, abdominal fat, insulin sen-
sitivity [22], and blood pressure [21]. Furthermore,
combined exercise is also beneficial for metabolic pa-
rameters [19, 20] and glucose variability in subjects
with type 2 diabetes [18]. However, as not all patients
tolerate conventional exercise and some find it difficult
to adhere to fitness programs, alternatives must be de-
veloped to enable these patients to obtain the benefits
of physical exercise. Inspiratory muscle training is a
novel exercise modality that has demonstrated impres-
sive beneficial effects on inspiratory muscle strength
and resistance [29, 50] and in reduction of glucose vari-
ability [30]. However, given the relatively small sample
size of our preliminary study [30], we planned to exam-
ine this question in greater depth through a new study
with a larger sample of patients with type 2 diabetes,
seeking to confirm that a single bout of inspiratory
muscle exercise may provide a benefit similar to that
achieved with aerobic exercise on glucose levels and
glucose variability. In brief, this study will be conducted
to evaluate glucose levels, glucose variability, and
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cardiovascular autonomic responses at rest, during, and
after a session of acute inspiratory muscle exercise
performed under two resistance loads (low, 2 % of
PImax; high, 60 % of PImax).
Trial status
The trial is currently in the recruitment phase. Each
patient is scheduled to attend nine hospital visits, and
the total data collection time will be 10 months.
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